TREMFYA^® has a convenient dosing regimen, with 6 doses per year in PsA and Pso¹

For PsA patients at high risk for joint damage according to clinical judgement, a dose of 100 mg every 4 weeks may be considered¹

In PsA clinical studies, an increased incidence of liver enzyme elevations was observed in patients treated with TREMFYA^® q4w compared to patients treated with TREMFYA^® q8w or placebo. When prescribing TREMFYA^® q4w in psoriatic arthritis, it is recommended to evaluate liver enzymes at baseline and thereafter according to routine patient management. If increases in ALT or AST are observed and drug-induced liver injury is suspected, TREMFYA^® should be temporarily interrupted until this diagnosis is excluded¹